Similar articles

• All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study.

  Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr. Frankel SR, et al. Ann Intern Med. 1994 Feb 15;120(4):278-86. doi: 10.7326/0003-4819-120-4-199402150-00004. Ann Intern Med. 1994. PMID: 8291820 Clinical Trial.
• Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid.

  Estey E, Koller C, Tsimberidou AM, O'Brien S, Beran M, Cortes J, Tirado-Gomez M, Lopez-Berestein G, Kantarjian H. Estey E, et al. Blood. 2005 Feb 1;105(3):1366-7. doi: 10.1182/blood-2004-09-3437. Blood. 2005. PMID: 15659618 Clinical Trial. No abstract available.
• Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid.

  Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Chen SJ, Huang XJ. Zhu HH, et al. Br J Haematol. 2016 Sep;174(5):820-2. doi: 10.1111/bjh.13809. Epub 2015 Nov 13. Br J Haematol. 2016. PMID: 27545413 Clinical Trial. No abstract available.
• All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia.

  Degos L, Dombret H, Chomienne C, Daniel MT, Micléa JM, Chastang C, Castaigne S, Fenaux P. Degos L, et al. Blood. 1995 May 15;85(10):2643-53. Blood. 1995. PMID: 7742522 Review. No abstract available.
• All trans retinoic acid in acute promyelocytic leukemia.

  Degos L, Castaigne S, Fenaux P, Daniel MT, Dombret H, Chomienne C. Degos L, et al. Nouv Rev Fr Hematol (1978). 1991;33(2):183-5. Nouv Rev Fr Hematol (1978). 1991. PMID: 1766850 Review. No abstract available.